Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03381274 · ClinicalTrials.gov registry record · Phase 1

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by MedImmune.

Active
Registry status
Phase 1
Development phase
43
Enrollment target
13
Study locations

NCT03381274 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by MedImmune. The registered enrollment target is 43 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (87% lower). The trial reports 13 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03381274, a Phase 1 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by MedImmune.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
43 participants
Enrollment target
13
Study locations

Study Summary

The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Osimertinib
  • BIOLOGICAL Oleclumab
  • DRUG AZD4635

Study Locations (13)

Other

  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Taichung

California

  • Research Site - La Jolla
  • Research Site - San Francisco

Colorado

  • Research Site - Aurora

Connecticut

  • Research Site - New Haven

Georgia

  • Research Site - Atlanta

Illinois

  • Research Site - Chicago

Maryland

  • Research Site - Baltimore

New York

  • Research Site - New York

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2018-05-08
Est. Completion 2026-04-16
Phase Phase 1

Sponsor

MedImmune

210 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03381274

The ClinicalTrials.gov registry entry for NCT03381274 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (87% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 3 interventions - of which Osimertinib is the first listed.

NCT03381274 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT03381274 about?

NCT03381274 is a clinical study titled "Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study". The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.

What is the current status of trial NCT03381274?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2018-05-08. Estimated completion is 2026-04-16.

What conditions does trial NCT03381274 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT03381274?

The interventions under investigation include: Osimertinib (DRUG), Oleclumab (BIOLOGICAL), AZD4635 (DRUG).

Who is sponsoring clinical trial NCT03381274?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03381274 being conducted?

This trial has 13 study locations across California, Colorado, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.